BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Rutgers Institute for Health - ECPv6.11.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rutgers Institute for Health
X-ORIGINAL-URL:https://ifh.rutgers.edu
X-WR-CALDESC:Events for Rutgers Institute for Health
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20260217T130000
DTEND;TZID=UTC:20260217T140000
DTSTAMP:20260824T073444
CREATED:20260115T220536Z
LAST-MODIFIED:20260206T175819Z
UID:6682-1771333200-1771336800@ifh.rutgers.edu
SUMMARY:NJ ACTS Special Populations Seminar with Princeton's Dr. Daniel A. Notterman
DESCRIPTION:The New Jersey Alliance for Clinical and Translational Science and IFH’s Center for Health Services Research presents: \nNJ ACTS Special Populations Seminar\nDaniel A. Notterman\, MA\, MD\, Professor & Vice Dean of Biomedical & Clinical Research\, Princeton University \n“Clinical\, Epidemiological\, and Molecular Insights from the Future of Families Cardiovascular Health Study” \nAs the original cohort of the Future of Families and Child Wellbeing Study enters early adulthood\, this lecture presents findings from a population-based sample of 2\,000 young adults examining how childhood adversity\, risk behaviors\, and social and demographic factors shape early cardiovascular health. We report associations between these exposures and multiple cardiovascular outcomes\, including the American Heart Association’s Life’s Essential 8 cardiovascular health score\, carotid intima–media thickness\, and related clinical and laboratory markers of atherosclerosis. At age 23\, specific risk behaviors were linked to poorer cardiovascular health and increased CIMT\, indicating early vascular disease. Longitudinal DNA methylation analyses at ages 9\, 15\, and 23 reveal that many of these abnormalities are associated with gene-specific methylation changes detectable by age 9\, which persist through adolescence into adulthood\, suggesting the emergence of an adverse epigenetic phenotype well before puberty. \nRegister to Attend: https://go.rutgers.edu/zdvwbsu \nDaniel is a pediatrician by clinical training and a biologist whose research examines interactions between genetic variants and environmental signals in the developing behavioral\, cognitive and emotional phenotype of the child. He wishes to understand the interactions between specific genetic variants\, environmental signals\, and resulting behavioral and health outcomes. As Vice Dean for Biomedical and Clinical Research\, Daniel supports the Office of the Dean for Research in facilitating Princeton’s growing portfolio of clinical research and other research that involves the use of biomaterials or biomedical health data obtained from human subjects. In this role\, he advises the Dean for Research\, the Institutional Review Board (IRB) chair\, and the Research Integrity & Assurance (RIA) director and staff on facilitating compliant clinical research.
URL:https://ifh.rutgers.edu/event/nj-acts-special-populations-seminar-with-princetons-dr-daniel-a-notterman/
LOCATION:Zoom
CATEGORIES:NJ ACTS
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260113T120000
DTEND;TZID=UTC:20260113T130000
DTSTAMP:20260824T073444
CREATED:20251223T201641Z
LAST-MODIFIED:20251223T201759Z
UID:6251-1768305600-1768309200@ifh.rutgers.edu
SUMMARY:NJ ACTS Special Populations Seminar with Arianna Campbell
DESCRIPTION:Join us on Tuesday\, January 13\, at 12 pm ET for a presentation of the NJ ACTS Special Populations Core 2026 Seminar Series – Increasing Access to MOUD: Direct to Inject Buprenorphine with Arianna Campbell\, DMSc\, MPH\, PA-C\, CAQ-EM\, DFAAPA \n\nIn this presentation\, we will highlight the rationale for Direct to Inject XR buprenorphine to improve access to life saving treatment for opioid use disorder. We will review the results of a recent national survey comparing emerging practices across the US. Finally\, we will review the algorithm that was recently released by the Bridge Center at PHI for emergency department administration of XR buprenorphine and the evidence behind it. \n\nArianna is an Emergency and Addiction Medicine PA with more than 26 years of clinical experience. She works in Emergency and Addiction Psychiatry as well as buprenorphine access at the VA in Sacramento and serves as Senior Director and M- Principal Investigator for The Bridge Center at PHI and CA Bridge\, a program for which she is a cofounder. She is President-elect for California Academy of Physician Associates and is a CE committee member and Presidential Taskforce member for ASAM. \n\nRegister for the seminar: https://go.rutgers.edu/ituguzkd
URL:https://ifh.rutgers.edu/event/nj-acts-special-populations-seminar-with-arianna-campbell/
LOCATION:Zoom
CATEGORIES:NJ ACTS
END:VEVENT
END:VCALENDAR